Canaccord analyst Whitney Ijem reiterated a Buy rating and $49.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst commented: "Over ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE